Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management

Mehdi Mirsaeidi; Pamela Barletta; Marilyn K. Glassberg

doi:10.3389/fmed.2019.00248

Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management

Mehdi Mirsaeidi, Pamela Barletta, Marilyn K. Glassberg

Research output: Contribution to journal › Review article › peer-review

21 Scopus citations

Abstract

A subgroup of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), characterized by inflammation and progressive scarring of the lungs that can lead to respiratory failure. Although ILD remains the major cause of death in these individuals, there is no consensus statement regarding the classification and characterization of SSc-related ILD (SSc-ILD). Recent clinical trials address the treatment of SSc-ILD and the results may lead to new disease-altering therapies. In this review, we provide an update to the diagnosis, management and treatment of SSc-ILD.

Original language	English (US)
Article number	248
Journal	Frontiers in Medicine
Volume	6
DOIs	https://doi.org/10.3389/fmed.2019.00248
State	Published - Oct 31 2019
Externally published	Yes

Keywords

cyclophosphamide
interstitial lung disease
nintedanib
pirfenidone
scleroderma
systemic sclerosis

ASJC Scopus subject areas

General Medicine

Access to Document

10.3389/fmed.2019.00248

Cite this

@article{67c285d4fb744156a28aaae37c7f6f4b,

title = "Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management",

abstract = "A subgroup of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), characterized by inflammation and progressive scarring of the lungs that can lead to respiratory failure. Although ILD remains the major cause of death in these individuals, there is no consensus statement regarding the classification and characterization of SSc-related ILD (SSc-ILD). Recent clinical trials address the treatment of SSc-ILD and the results may lead to new disease-altering therapies. In this review, we provide an update to the diagnosis, management and treatment of SSc-ILD.",

keywords = "cyclophosphamide, interstitial lung disease, nintedanib, pirfenidone, scleroderma, systemic sclerosis",

author = "Mehdi Mirsaeidi and Pamela Barletta and Glassberg, {Marilyn K.}",

note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2019 Mirsaeidi, Barletta and Glassberg.",

year = "2019",

month = oct,

day = "31",

doi = "10.3389/fmed.2019.00248",

language = "English (US)",

volume = "6",

journal = "Frontiers in Medicine",

issn = "2296-858X",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Systemic Sclerosis Associated Interstitial Lung Disease

T2 - New Directions in Disease Management

AU - Mirsaeidi, Mehdi

AU - Barletta, Pamela

AU - Glassberg, Marilyn K.

PY - 2019/10/31

Y1 - 2019/10/31

N2 - A subgroup of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), characterized by inflammation and progressive scarring of the lungs that can lead to respiratory failure. Although ILD remains the major cause of death in these individuals, there is no consensus statement regarding the classification and characterization of SSc-related ILD (SSc-ILD). Recent clinical trials address the treatment of SSc-ILD and the results may lead to new disease-altering therapies. In this review, we provide an update to the diagnosis, management and treatment of SSc-ILD.

AB - A subgroup of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), characterized by inflammation and progressive scarring of the lungs that can lead to respiratory failure. Although ILD remains the major cause of death in these individuals, there is no consensus statement regarding the classification and characterization of SSc-related ILD (SSc-ILD). Recent clinical trials address the treatment of SSc-ILD and the results may lead to new disease-altering therapies. In this review, we provide an update to the diagnosis, management and treatment of SSc-ILD.

KW - cyclophosphamide

KW - interstitial lung disease

KW - nintedanib

KW - pirfenidone

KW - scleroderma

KW - systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85075380408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075380408&partnerID=8YFLogxK

U2 - 10.3389/fmed.2019.00248

DO - 10.3389/fmed.2019.00248

M3 - Review article

AN - SCOPUS:85075380408

SN - 2296-858X

VL - 6

JO - Frontiers in Medicine

JF - Frontiers in Medicine

M1 - 248

ER -

Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this